International conference sits at the center of this dementia and brain health question.

The international Alzheimer’s research community is converging on multiple major conferences throughout 2026 to present groundbreaking advances in drug development and treatment strategies. The AD/PD™ 2026 Conference in Copenhagen this March is hosting over 5,500 participants from 70 countries with 2,500+ abstracts, establishing it as one of the year’s pivotal forums for Alzheimer’s drug research.

Pharmaceutical companies like Eisai are presenting critical new data on anti-amyloid therapies like lecanemab, while researchers are sharing insights on treatment persistence, genetic response factors, and early detection methods that could reshape how Alzheimer’s is diagnosed and managed. Beyond Copenhagen, the research calendar remains packed: the Alzheimer’s Society International Congress in San Francisco (May), the world’s largest dementia research conference AAIC in London (July), and specialized symposiums on emerging biomarkers and novel therapeutic mechanisms. This article covers what these major conferences are revealing about the latest Alzheimer’s drug research, which therapies are showing promise in real-world settings, and what these scientific breakthroughs mean for patients and caregivers navigating this disease.

Where Is the Latest Alzheimer’s Drug Research Being Presented?
What New Alzheimer’s Drug Discoveries Are Being Presented?
Lecanemab and Anti-Amyloid Beta Treatments: What the Research Shows
Real-World Treatment Data and Long-Term Outcomes
Genetic Factors and Personalized Alzheimer’s Treatment
Early Detection and Prevention Strategies in Focus
What These Conference Breakthroughs Mean for Alzheimer’s Care
Conclusion

Where Is the Latest Alzheimer’s Drug Research Being Presented?

The AD/PD™ 2026 Conference in Copenhagen (March 17-21) represents the current epicenter of Alzheimer’s drug discovery discussions. with participation from over 70 countries and nearly 2,500 submitted abstracts, the conference draws neurologists, researchers, pharmaceutical representatives, and clinicians focused on Alzheimer’s and Parkinson’s disease. Eisai, a major player in Alzheimer’s drug development, will present six separate presentations on lecanemab—an anti-amyloid beta protofibril antibody—including three oral presentations covering U.S. real-world treatment data and outcomes in specific genetic populations.

Looking ahead, the Alzheimer’s Society International Congress (ASIC 2026) convenes in San Francisco on May 18-20, followed by the Alzheimer’s Association International Conference (AAIC 2026) in London July 12-15, which streams online globally. AAIC is recognized as the world’s largest forum for the dementia research community, making it essential for anyone tracking clinical advances. The Alzheimer’s Insights Summit 3 in Copenhagen operates as an invite-only symposium, focusing on the full continuum from prevention and diagnostics through treatment innovations. However, the scale of these conferences means that not all presented research will translate to immediate clinical availability—many findings require years of validation and regulatory approval before reaching patients.

Where Is the Latest Alzheimer's Drug Research Being Presented?

What New Alzheimer’s Drug Discoveries Are Being Presented?

The central theme uniting 2026’s conferences is anti-amyloid beta antibody therapy, particularly lecanemab and similar agents that target amyloid-beta protofibril accumulation in the brain. These drugs represent a shift in Alzheimer’s treatment philosophy—rather than managing symptoms, anti-amyloid therapies aim to slow cognitive decline by addressing a root cause of the disease. At AD/PD 2026, Eisai is presenting real-world data from the United States showing how long patients continue lecanemab treatment and whether they’re achieving the cognitive benefits seen in clinical trials.

Additional research focuses on apolipoprotein E (ApoE) genetic variations and treatment response. The APOE ε4 gene variant is a known risk factor for developing Alzheimer’s disease, and researchers are now examining whether people carrying this gene respond differently to lecanemab and similar anti-amyloid drugs. This personalization angle is critical because it could eventually allow doctors to predict which patients will benefit most from these expensive, infusion-based therapies. The conferences also highlight translational R&D updates and ongoing clinical trial data—meaning researchers are bridging bench science discoveries with human treatment applications and publishing what they’re learning about efficacy, safety, and durability.

Lecanemab and Anti-Amyloid Beta Treatments: What the Research Shows

Lecanemab (marketed as Leqembi) functions as a humanized monoclonal antibody targeting amyloid-beta protofibrils—the smaller, toxic clusters of amyloid that accumulate in Alzheimer’s disease. Unlike older symptomatic treatments, lecanemab addresses the pathology driving the disease, offering the potential to slow cognitive decline in early-stage Alzheimer’s patients. The clinical trial data demonstrated a slowing of cognitive decline in people with mild cognitive impairment or mild dementia, though the absolute benefit is measured in months of delayed progression rather than reversal of existing damage.

A limitation of lecanemab worth understanding: the drug requires regular IV infusions (infusions occur every two weeks), carries a risk of amyloid-related imaging abnormalities (ARIA) on brain MRI scans, and is only approved for early-stage disease. Not all patients tolerate the infusions, and amyloid burden on imaging doesn’t always correlate perfectly with cognitive symptoms. The real-world data Eisai is presenting at AD/PD 2026 will show how many patients continue the treatment long-term and whether they experience the cognitive benefits researchers hope for outside the controlled trial setting—data that’s crucial because clinical trials don’t always predict real-world persistence or outcomes.

Lecanemab and Anti-Amyloid Beta Treatments: What the Research Shows

Real-World Treatment Data and Long-Term Outcomes

While clinical trials provide proof-of-concept for new Alzheimer’s drugs, real-world evidence reveals how treatments perform in everyday medical practice. Eisai’s presentation on U.S. treatment persistence is examining how long patients actually stay on lecanemab therapy—whether they complete the planned infusion schedule, whether they experience side effects that cause them to stop, and whether cognitive benefits hold up over months of actual use. This distinction matters because some patients drop out of real-world treatment due to logistical challenges (frequent clinic visits), tolerability issues, or lack of perceived benefit, even if the drug worked well in trials.

The comparison between clinical trial efficacy and real-world effectiveness is crucial for caregivers and patients deciding whether lecanemab is right for them. In the Clarity AD trial, lecanemab showed a 35% slowing of cognitive decline at 18 months—meaningful but not a cure. In real-world use, some patients experience this benefit while others don’t, and a subset experience ARIA (brain microhemorrhages or microinfarcts visible on MRI) that requires stopping the drug. The conferences are highlighting this gap between ideal trial conditions and messy real-world application, allowing clinicians to better counsel patients about realistic expectations and which individuals are most likely to tolerate and benefit from anti-amyloid therapy.

Genetic Factors and Personalized Alzheimer’s Treatment

The APOE ε4 gene variant carries significant weight in Alzheimer’s risk. People with two copies of the ε4 variant face a much higher lifetime risk of developing Alzheimer’s, and historically, this group has been underrepresented in clinical trials. AD/PD 2026 includes presentations specifically examining lecanemab outcomes in apolipoprotein E ε4 homozygous carriers—people with two copies of the high-risk variant. Understanding whether these genetically vulnerable individuals respond differently to anti-amyloid therapy could reshape treatment stratification.

However, genetic markers like APOE status are not destiny. Some ε4 carriers never develop Alzheimer’s, while some people without ε4 variants do. The research emerging from these conferences is examining response patterns, not predicting individual outcomes. Additionally, APOE is just one of many genetic risk factors, and the polygenic risk score for Alzheimer’s involves dozens of genes. The implication for patients: genetic testing might eventually guide treatment selection, but it’s not yet standard practice, and genetic risk doesn’t determine whether someone should or shouldn’t pursue anti-amyloid therapy based solely on their APOE status.

Genetic Factors and Personalized Alzheimer's Treatment

Early Detection and Prevention Strategies in Focus

A major theme across the 2026 conferences is early detection—identifying people at risk or in the earliest stages of Alzheimer’s before significant cognitive symptoms emerge. The Alzheimer’s Insights Summit 3 specifically focuses on the continuum from prevention to diagnostics to treatment, exploring emerging biomarkers that can detect amyloid and tau accumulation years before cognitive decline. Blood biomarkers like phosphorylated tau and plasma phospho-tau are game-changers because they’re far cheaper and more accessible than PET imaging or cerebrospinal fluid analysis.

If blood biomarkers enable early identification, prevention becomes possible. Early anti-amyloid therapy in asymptomatic people with amyloid pathology might prevent Alzheimer’s symptoms from ever manifesting. However, treating asymptomatic people raises questions about long-term safety, benefit-risk ratios, and who should be screened. These discussions at major conferences will shape clinical guidelines over the next 2-3 years, but for now, the field is still defining who benefits from early intervention versus who should wait for symptoms.

What These Conference Breakthroughs Mean for Alzheimer’s Care

The sheer scale and focus of 2026’s Alzheimer’s conferences—5,500+ researchers in Copenhagen alone, hundreds of presentations, and new data on multiple anti-amyloid drugs and prevention strategies—reflects a field in motion. We’re no longer in an era where symptom management is the primary goal; disease-modifying therapy is the new frontier. The research being presented will likely influence clinical guidelines, insurance coverage decisions, and which patients get referred for drug trials in the coming months.

For families and patients, this means conversations with neurologists are evolving. Instead of “there’s no disease-modifying treatment,” the conversation is shifting to “do you qualify for and want to pursue anti-amyloid therapy, given the benefits and risks?” The conferences happening in Copenhagen, San Francisco, and London over the next few months will crystallize what we know about these drugs’ real-world performance, genetic response patterns, and opportunities for earlier intervention. The research community is laying the groundwork for a future where Alzheimer’s might be detected and treated before irreversible cognitive damage occurs.

Conclusion

The international Alzheimer’s drug research conferences in 2026 represent a pivotal moment in how the field approaches this disease. Major gatherings in Copenhagen (AD/PD and Insights Summit), San Francisco (ASIC), and London (AAIC) are presenting critical data on anti-amyloid therapies like lecanemab, real-world treatment outcomes, genetic factors that influence drug response, and emerging prevention strategies. These conferences aren’t academic exercises—the research shapes clinical practice, treatment guidelines, and which patients clinicians offer new therapies to.

If you or a loved one is navigating an Alzheimer’s diagnosis, the advances being presented at these conferences are worth discussing with your neurologist. Ask whether early detection through blood biomarkers is appropriate, whether anti-amyloid therapy might be beneficial based on disease stage and genetics, and what the real-world evidence shows about treatment durability and outcomes. The research pipeline remains active and evolving, and staying informed about what’s being presented at major conferences helps patients and caregivers make decisions rooted in the latest evidence rather than outdated assumptions about Alzheimer’s treatment options.